NCT01897714 · REGISTRY CONDITION SEARCH

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2020-10-23

The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen. That dose will then be used to determine the efficacy and safety profile of melflufen in combination with dexamethasone in a larger group of patients.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Patients Who Achieved Best Overall Disease Response

→

outcome · POSTED

Overall Response Rate (ORR)

→

outcome · POSTED

Clinical Benefit Response Rate (CBRR)

→

outcome · POSTED

Duration of Disease Response (DOR)

→

outcome · POSTED

Time to Disease Response in Patients Who Achieved OR and CBR

→

outcome · POSTED

Time to Disease Progression

→

outcome · POSTED

Median Progression-Free Survival (PFS)

→

outcome · POSTED

Median Overall Survival (OS)

→

outcome · POSTED

Time to First Subsequent Treatment

→

outcome · POSTED

Number of Patients With Treatment Emergent Adverse Events (TEAEs)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Male or female, age 18 years or older 2. Patient has a diagnosis of multiple myeloma with documented relapsed and/or relapsed-refractory disease 3. Patient has measurable disease defined as any of the following: 1. Serum monoclonal protein ≥ 0.5 g/dL by protein electrophoresis 2. ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis 3. Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio 4. If no monoclonal protein is detected, then ≥ 30% monoclonal bone marrow plasma cells 4. Patient has had at least 2 or more prior lines of therapy including lenalidomide and bortezomib and has demonstrated disease progression on or within 60 days of completion of the last therapy 5. Life expectancy of ≥6 months 6. Patient has an ECOG performance status ≤ 2 (Patients with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible) 7. Females of childbearing potential must have a negative serum or urine pregnancy test prior to patient registration 8. Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control 9. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information 10. The patient has, or accepts to have, an acceptable infusion device for infusion of melflufen 11. 12 lead ECG with QtcF interval ≤ 470 msec 12. The following laboratory results must be met within 21 days of patient registration: * Absolute neutrophil count ≥ 1,000 cells/dL (1.0 x 109/L) * Platelet count ≥ 75,000 cells/dL (75 x 109/L) * Hemoglobin ≥ 8.0 g/dL * Total Bilirubin ≤ 1.5 x upper limit of normal * Renal function: Estimated creatinine clearance ≥ 45 ml/min or serum creatinine ≤ 2.5 mg/dL * AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN Exclusion Criteria: 1. Patient has evidence of mucosal or internal bleeding and/or is platelet transfusion refractory 2. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participation in this study 3. Known active infection requiring parenteral or oral anti-infective treatment 4. Other malignancy within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix 5. Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration. 6. Pregnant or breast-feeding females 7. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation 8. Known HIV or hepatitis B or C viral infection 9. Patient has concurrent symptomatic amyloidosis or plasma cell leukemia 10. POEMS syndrome 11. Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to start of study treatment. Biologic, novel therapy (including investigational agents in this class) or corticosteroids within 2 weeks prior to patient registration. Patient has side effects of the previous therapy \> grade 1 or previous baseline. 12. Prior peripheral stem cell transplant within 12 weeks of patient registration 13. Radiotherapy within 21 days prior to Cycle 1 Day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy 14. Known intolerance to steroid therapy
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
intervention Names
Drug: Melflufen
Drug: Dexamethasone
label
Phase I: Melflufen 15 mg + Dexamethasone
type
EXPERIMENTAL
description
IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
intervention Names
Drug: Melflufen
Drug: Dexamethasone
label
Phase I: Melflufen 25 mg + Dexamethasone
type
EXPERIMENTAL
description
IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
intervention Names
Drug: Melflufen
Drug: Dexamethasone
label
Phase I: Melflufen 40 mg + Dexamethasone
type
EXPERIMENTAL
description
IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
intervention Names
Drug: Melflufen
Drug: Dexamethasone
label
Phase I: Melflufen 55 mg + Dexamethasone
type
EXPERIMENTAL
description
IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
intervention Names
Drug: Melflufen
Drug: Dexamethasone
label
Phase I + II: Melflufen 40 mg + Dexamethasone
type
EXPERIMENTAL
description
IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
intervention Names
Drug: Melflufen
label
Phase II: Melflufen 40 mg (Single Agent)
type
EXPERIMENTAL

interventions

arm Group Labels
Phase I + II: Melflufen 40 mg + Dexamethasone
Phase I: Melflufen 15 mg + Dexamethasone
Phase I: Melflufen 25 mg + Dexamethasone
Phase I: Melflufen 40 mg + Dexamethasone
Phase I: Melflufen 55 mg + Dexamethasone
Phase II: Melflufen 40 mg (Single Agent)
name
Melflufen
type
DRUG
arm Group Labels
Phase I + II: Melflufen 40 mg + Dexamethasone
Phase I: Melflufen 15 mg + Dexamethasone
Phase I: Melflufen 25 mg + Dexamethasone
Phase I: Melflufen 40 mg + Dexamethasone
Phase I: Melflufen 55 mg + Dexamethasone
name
Dexamethasone
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 75
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The best overall disease response on treatment including stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) or progressive disease (PD) were evaluated. Starting on completion of Cycle 2, response was assessed according to International Myeloma Working Group (IMWG) criteria based on Investigator's assessment for all patients at every cycle during treatment period. PD was defined as increase of ≥25% from lowest response value in any 1 of the following: serum M-component (absolute increase must be ≥0.5 gram/deciliter) and/or urine M-component (absolute increase must be ≥200 mg/24 hr); development of new bone lesions or soft tissue plasmacytomas or increase in size of existing bone lesions or soft tissue plasmacytomas or development of hypercalcemia that could be attributed solely to plasma cell proliferative disorder. SD was defined as not meeting criteria for CR, VGPR, PR or PD.
measure
Percentage of Patients Who Achieved Best Overall Disease Response
time Frame
Baseline (Cycle 1 Day 1) and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
ORR was defined as percentage of patients with an overall response (OR), defined as first occurrence of confirmed disease response including PR or better (i.e, PR, VGPR, CR or sCR). Starting on completion of Cycle 2, response was assessed according to IMWG criteria based on Investigator's assessment for all patients at every cycle during treatment period. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum plus urine M-protein level \<100 mg/24hr and \>90% decrease in difference between involved and uninvolved free light chain (FLC) levels (only in FLC diseased patients). CR was defined as negative immunofixation on serum and urine, loss of any soft tissue plasmacytomas, \<5% plasma cells in bone marrow and normal FLC ratio of 0.26 to 1.65 (only in FLC diseased patients). sCR was defined as CR plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or 2 to 4 color flow cytometry.
measure
Overall Response Rate (ORR)
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
The CBRR was defined as the percentage of patients with a clinical benefit response (CBR), defined as the first occurrence of confirmed disease response including MR or better (i.e, MR, PR, VGPR, CR, or sCR). Starting on completion of Cycle 2, response was assessed according to the IMWG criteria based on the Investigator's assessment for all patients at every cycle during the treatment period. MR was defined as ≥25% but \<49% reduction of serum M-protein and reduction in 24 hour urine M-protein by 50 to 89%, which still exceeds 200 mg/24 hours. In addition to above; if present at baseline, 25 to 49% reduction in the size of soft tissue plasmacytomas is also required. No increase in size or number of lytic bone lesions (development of compression fractures does not exclude response). PR was defined as 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by ≥90% or to \<200 mg/24 hour.
measure
Clinical Benefit Response Rate (CBRR)
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.

secondary Outcomes

description
The DOR to treatment was defined as time from first response (PR or better) to disease progression or death, or date of last evaluable disease response assessment for those who had not progressed or died. DOR was estimated using Kaplan-Meier statistics.
measure
Duration of Disease Response (DOR)
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
Time to first OR was defined as the time from the date of the first dose of study drug (overall reference start date) to the date of the first occurrence of PR or better (first of 2 consecutive assessments-confirmed response). Time to first CBR was defined as the time from the date of the first dose of study drug (overall reference start date) to the date of the first occurrence of MR or better (first of 2 consecutive assessments-confirmed response). Time to disease response was estimated using Kaplan-Meier statistics.
measure
Time to Disease Response in Patients Who Achieved OR and CBR
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
Time to disease progression was defined as the time from the date of the first dose of study drug (overall reference start date) to the date of the first occurrence of evaluable PD. Time to disease progression was estimated using Kaplan-Meier statistics.
measure
Time to Disease Progression
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
The PFS was defined as the time from the date of the first dose of melflufen (overall reference start date) to the date of the first occurrence of any disease response assessment available for PD or death. The PFS was estimated using Kaplan-Meier statistics.
measure
Median Progression-Free Survival (PFS)
time Frame
Baseline and every cycle from Cycle 2 onwards until confirmed disease progression. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
The OS was defined as the time from the date of the first dose of melflufen (overall reference start date) to death. The OS was estimated using Kaplan-Meier statistics.
measure
Median Overall Survival (OS)
time Frame
From baseline until death. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
Time to first subsequent treatment start was defined as the time from the date of the actual end of treatment to the date of the first subsequent treatment. Time to first subsequent treatment was estimated using Kaplan-Meier statistics.
measure
Time to First Subsequent Treatment
time Frame
From baseline until start of first subsequent treatment. Assessed until EOT date of 29 October 2019; up to a maximum of approximately 76 months.
description
An adverse event (AE) was any untoward medical occurrence in a study patient administered an investigational product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was defined as any AE, occurring at any dose, that met any one or more of the following criteria: is fatal or immediately life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization; or other important medical event. TEAEs were defined as AEs that started or worsened on or after the first dose of study drug (overall reference start date) up to and including the actual EOT date. TESAEs = Treatment emergent serious adverse events.
measure
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
time Frame
From the first dose of study drug up to and including the actual EOT date of 29 October 2019; up to a maximum of approximately 76 months.

Full study description

brief Summary: The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen. That dose will then be used to determine the efficacy and safety profile of melflufen in combination with dexamethasone in a larger group of patients.

Source references

references

citation
Richardson PG, Bringhen S, Voorhees P, Plesner T, Mellqvist UH, Reeves B, Paba-Prada C, Zubair H, Byrne C, Chauhan D, Anderson K, Nordstrom E, Harmenberg J, Palumbo A, Sonneveld P. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
pmid
32213344
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-c6f7d4922573f5d00f6d
requested nct id
NCT01897714
primary nct id
NCT01897714
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ
source record id
Source null
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
payload sha256
b95490af433bf9ecb960894c08ad82b101e601833c4e991a1003800e3475fcc4
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-c6f7d4922573f5d00f6d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01897714
occurrences
context exact
NCT01897714
end
11
exact text
NCT01897714
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
source json pointer
/studies/34/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0efa4ccfc891dd46660da73c70c49bd67cedb8fd2316e8c03c964e9e1988a9e5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ

Preserved source evidence · Not medical advice